FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

Brain cancer vax promising in PhI

Tools

A small Phase I trial of an experimental dendritic cell-based brain cancer vaccine advanced by ImmunoCellular Therapeutics (IMUC) has produced some unusually positive results. Only 16 patients suffering from glioblastoma multiforme--the most common of all brain cancers--were recruited for the study. But researchers report that 18 months after treatment began, almost half of the patients were still alive without any worsening of their disease. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about brain   ImmunoCellular Therapeutics  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.